Yohei Matsui
Overview
Explore the profile of Yohei Matsui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
684
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katayama Y, Yamada T, Tanimura K, Kawachi H, Ishida M, Matsui Y, et al.
Clin Cancer Res
. 2024 Nov;
PMID: 39495173
Purpose: Rearranged during transfection (RET) aberrations represent a targetable oncogene in several tumor types, with RET inhibitors displaying marked efficacy. However, some patients with RET-aberrant cancer are insensitive to RET...
2.
Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, et al.
Cancer Lett
. 2024 Jul;
598:217124.
PMID: 39059573
We previously reported that combined therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and AXL inhibitor ONO-7475 is effective in preventing the survival of drug-tolerant cells in...
3.
Matsui Y, Yamada T, Katayama Y, Hirai S, Sawada R, Tachibana Y, et al.
Cancer Sci
. 2024 Jul;
115(10):3333-3345.
PMID: 39039802
Lazertinib, a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), demonstrates marked efficacy in EGFR-mutant lung cancer. However, resistance commonly develops, prompting consideration of therapeutic strategies to overcome...
4.
Hirayama H, Takaki Y, Abe M, Miyazaki M, Uematsu K, Matsui Y, et al.
Int J Syst Evol Microbiol
. 2024 Mar;
74(3).
PMID: 38478579
A novel aerobic methanotrophic bacterium, designated as strain IN45, was isolated from colonisation systems deployed at the Iheya North deep-sea hydrothermal field in the mid-Okinawa Trough. IN45 was a moderately...
5.
Morimoto K, Yamada T, Hirai S, Katayama Y, Fukui S, Sawada R, et al.
Cancer Lett
. 2024 Feb;
587:216692.
PMID: 38342232
Recently, novel Kirsten rat sarcoma viral oncogene homolog (KRAS) inhibitors have been clinically developed to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC) patients. However, achieving complete tumor remission is...
6.
Hirai S, Yamada T, Katayama Y, Ishida M, Kawachi H, Matsui Y, et al.
Mol Cancer Ther
. 2023 Oct;
23(2):212-222.
PMID: 37802502
Few treatment options exist for pleural mesothelioma (PM), which is a progressive malignant tumor. However, the efficacy of molecular-targeted monotherapy is limited, and further therapeutic strategies are warranted to treat...
7.
Takahagi W, Okada S, Matsui Y, Ono S, Takai K, Takahashi Y, et al.
Proc Natl Acad Sci U S A
. 2023 Oct;
120(41):e2303302120.
PMID: 37782799
An increasing amount of evidence suggests that early ocean hydrothermal systems were sustained sources of ammonia, an essential nitrogen species for prebiotic synthesis of life's building blocks. However, it remains...
8.
Nakamura R, Fujii H, Yamada T, Matsui Y, Yaoi T, Honda M, et al.
JTO Clin Res Rep
. 2023 Jul;
4(6):100525.
PMID: 37426308
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the...
9.
Morita-Tanaka S, Miyagawa-Hayashino A, Yamada T, Matsui Y, Morimoto K, Hiranuma O, et al.
Support Care Cancer
. 2023 Apr;
31(5):308.
PMID: 37115357
Purpose: Growth differentiation factor-15 (GDF-15) is one of the key cachexia-inducing factors. Clinical trials on therapies targeting GDF-15 for cancer and cancer cachexia are underway. While the role of circulating...
10.
Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, et al.
NPJ Precis Oncol
. 2023 Jan;
7(1):12.
PMID: 36702855
Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors rarely elicit complete responses in patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC), as a small population of tumor cells survives due to...